Showing 15 posts of 294 posts found.

Data published on novel molecules for leukaemia treatment

April 27, 2021
Manufacturing and Production oncology

STORM Therapeutics have published new data in Nature on targeting RNA modifying enzymes for the development of new anti-cancer therapeutics, …


Enhertu now available via Cancer Drugs Fund following NICE decision

April 20, 2021
Manufacturing and Production AstraZeneca, breast cancer, oncology

AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …


TILT Biotherapeutics & MSD to collaborate on adenoviral cancer immunotherapy trial

April 14, 2021
Research and Development clinical trial, oncology

TILT Biotherapeutics today announced a clinical trial collaboration agreement with MSD, to evaluate TILT’s adenoviral cancer immunotherapy, TILT-123, in combination …

Exscientia enter first-ever AI cancer drug into Phase I trials

April 9, 2021
Medical Communications AI, Evotec, Exscientia, cancer treatment, oncology, pharma, pharma news

Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first …

Novartis and Artios Pharma to collaborate on DDR cancer therapies

April 7, 2021
Research and Development Novartis, RLT, oncology

Novartis and Artios Pharma have announced a global research collaboration to discover and validate next generation DNA damage response (DDR) …

EC approves combination treatment for kidney cancer

March 31, 2021
Research and Development Cancer, Europe, oncology

The European Commission (EC) has approved Ipsen’s Cabometyx in combination with Opdivo as a first-line treatment for advanced renal cell …


Astellas Pharma and Seagen cancer treatment gets MAA acceptance from EMA

March 26, 2021
Medical Communications EMA, oncology

Astellas Pharma and Seagen Inc. have announced that the EMA has accepted their marketing authorisation application (MAA) for enfortumab vedotin, …


Incyte biliary tract cancer treatment approved in Japan

March 23, 2021
Manufacturing and Production EMA, Japan, oncology

The Japanese Ministry of Health, Labour, and Welfare (MHLW) have approved Incyte’s Pemazyre (pemigatinib) for the treatment of patients with …


Accord Healthcare launches thalidomide for multiple myeloma treatment

March 23, 2021
Manufacturing and Production MHRA, oncology

Accord Healthcare has announced the UK launch of a generic thalidomide, which is used in combination with melphalan and prednisone, …

Novartis prostate cancer treatment sees positive Phase III results

March 23, 2021
Manufacturing and Production Novartis, oncology

Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …


Roche lung cancer treatment reports promising results in Phase III

March 22, 2021
Sales and Marketing Roche, oncology

Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …

NICE recommends new triple therapy for multiple myeloma patients

March 19, 2021
Medical Communications NHS England, NICE, oncology

A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …

Complix and I-Mab sign deal to develop alphabody cancer therapies

March 11, 2021
Cancer, Complix, oncology

Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, …


Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+

September 2, 2020
Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma

Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …

Latest content